Cardiovascular Risk Assessment

Device Innovations: The Next Generation of Cardiovascular Technologies

by Prateek Chopra | June 19, 2026 | Cardiology Conferences | ESH 2026 Study Background: Advances in cardiology are driving novel devices and techniques for cardiovascular disease management. Emerging technologies aim to improve monitoring, diagnostics, and personalized care, particularly in hypertension and cardiovascular risk assessment. Key Innovations: Cuffless and Wearable Blood Pressure Monitoring: Rings, watches, and wristbands enable continuous, convenient out-of-office […]

Device Innovations: The Next Generation of Cardiovascular Technologies Read Post »

Leave a Comment / ESH Day 4 / / / , , , ,

Frequency and Predictive Factors of White-Coat Hypertension in Grade 1 Hypertensive Patients: Results of the Hungarian ABPM Registry

by Prateek Chopra | June 14, 2026 | Cardiology Conferences | ESH 2026 Study Focus: Assess the prevalence of white-coat hypertension (WCH) in patients with grade 1 hypertension (gr. 1 HT) and identify predictive factors distinguishing WCH from sustained hypertension. Study Design: Key Findings: Clinical Implications: WCH affects a substantial proportion of patients with grade 1 hypertension, particularly among women, older

Frequency and Predictive Factors of White-Coat Hypertension in Grade 1 Hypertensive Patients: Results of the Hungarian ABPM Registry Read Post »

Leave a Comment / ESH Day 3 / / / , , ,

Integrated Polygenic Scores: Are They Ready for Clinical Practice?

by Prateek Chopra | June 7, 2026 | Cardiology Conferences | ESH 2026 Precision Cardiovascular Prevention: Integrated polygenic risk scores (PRS) enhance risk stratification beyond traditional risk factors. PRS predicts coronary artery disease (CAD) 2–4 times more strongly than conventional risk factors and identifies high-risk individuals not captured by family history or standard clinical assessments. High-Risk Populations: Evidence from Clinical Trials:

Integrated Polygenic Scores: Are They Ready for Clinical Practice? Read Post »

Leave a Comment / ESH Day 2 / / / , , , ,

Treatment Algorithms for Hypertensive Patients with Hyperlipidaemia and Diabetes, Including Management Beyond Triple Combination Therapy

by Prateek Chopra | June 7, 2026 | Cardiology Conferences | ESH 2026 Optimizing Cardiovascular Risk: Prof. Andrzej highlighted standardized CVD mortality rates across regions, emphasizing major risk factors including BMI, systolic blood pressure, non-HDL cholesterol, diabetes, and smoking. Expanded clinical conditions such as resistant hypertension, sleep disorders, chronic inflammation, NAFLD, and migraine, as well as emerging risk factors like sedentary

Treatment Algorithms for Hypertensive Patients with Hyperlipidaemia and Diabetes, Including Management Beyond Triple Combination Therapy Read Post »

Leave a Comment / ESH Day 2 / / / , , , ,

Implementing the PREVENT Risk Equation in the 2025 Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults

by Prateek Chopra | June 1, 2026 | Cardiology Conferences | ESH 2026 Clinical Background: Accurate cardiovascular risk assessment is central to hypertension management and prevention strategies. Contemporary approaches emphasize integrated cardiovascular-kidney-metabolic (CKM) risk evaluation to improve early detection, individualized therapy, and long-term cardiovascular outcomes. Evidence & Risk Tools: Implementation Strategies: Clinical Implications: Structured integration of CKM risk assessment, validated

Implementing the PREVENT Risk Equation in the 2025 Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults Read Post »

Leave a Comment / ESH Day 1 / / / , , , ,
Scroll to Top